Cargando…

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer

Axillary management after NET has not been well studied and the significance of residual axillary node disease after NET remains uncertain. We used the National Cancer Data Base to examine the prognostic significance of residual nodal disease after NET. From 2010–2016, 4,496 patients received NET fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kantor, Olga, Wong, Stephanie, Weiss, Anna, Metzger, Otto, Mittendorf, Elizabeth A., King, Tari A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426953/ https://www.ncbi.nlm.nih.gov/pubmed/32821803 http://dx.doi.org/10.1038/s41523-020-00177-6

Ejemplares similares

Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2020)

Regional nodal irradiation (RNI) in breast cancer patients with residual isolated tumor cells or micrometastatic nodal disease after neoadjuvant chemotherapy
por: Kim, Joseph K., et al.
Publicado: (2022)

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2021)

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy
por: Reis, Joana, et al.
Publicado: (2022)

Long‐term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status
por: Zetterlund, L, et al.
Publicado: (2021)

Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics †
por: Chiappetta, Marco, et al.
Publicado: (2022)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Low-Volume Nodal Metastasis in Endometrial Cancer: Risk Factors and Prognostic Significance
por: García Pineda, Virginia, et al.
Publicado: (2020)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Prediction of Residual Axillary Nodal Metastasis Following Neoadjuvant Chemotherapy for Breast Cancer: Radiomics Analysis Based on Chest Computed Tomography
por: Lee, Hyo-jae, et al.
Publicado: (2023)

Histological Regression of Squamous Esophageal Carcinoma Assessed by Percentage of Residual Viable Cells after Neoadjuvant Chemoradiation is an Important Prognostic Factor
por: Tong, Daniel King Hung, et al.
Publicado: (2010)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Assessment of Oncologists’ Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor–Positive Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2022)

Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer
por: Aziz, Sura, et al.
Publicado: (2017)

Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study
por: Rogé, Maximilien, et al.
Publicado: (2022)

The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy
por: Oner, Gizem, et al.
Publicado: (2023)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

The Prognostic Significance of Metastatic Nodal Size in Non-surgical Patients With Esophageal Squamous Cell Carcinoma
por: Zhao, Zongxing, et al.
Publicado: (2020)

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer
por: Cascone, Tina, et al.
Publicado: (2021)

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy
por: Kandula, Shravan, et al.
Publicado: (2015)

The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study
por: Martí, Covadonga, et al.
Publicado: (2022)

ASO Author Reflections: Residual Disease in the Breast Following Neoadjuvant Chemotherapy Does Not Mandate Routine Post-Mastectomy Radiation Therapy/Regional Nodal Irradiation
por: Crown, Angelena, et al.
Publicado: (2020)

MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison
por: Zhang, Zhiwen, et al.
Publicado: (2023)

Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma
por: Chen, Xi, et al.
Publicado: (2020)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Hormone Production in Endocrine Tumours
por: Abelson, Denis
Publicado: (1958)

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Management of synchronous lateral pelvic nodal metastasis in rectal cancer in the era of neoadjuvant chemoradiation: A systemic review
por: Wong, Jolene Si Min, et al.
Publicado: (2020)

An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment
por: Yoo, Tae-Kyung, et al.
Publicado: (2017)

Internal mammary lymph nodal response to neoadjuvant chemotherapy on imaging and breast cancer prognosis
por: Adam, Richard, et al.
Publicado: (2022)

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
por: Hermida-Prado, Francisco, et al.
Publicado: (2023)

Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis
por: Kolberg, Hans-Christian, et al.
Publicado: (2020)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

Effects of Hormones and Endocrine Disorders on Hair Growth
por: Hasan, Rishi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_92f56k384qli97fmsrmdsu2bie